View Cart
My AccountInfectious Disease Diagnostic Solutions
Microbix Phone+1803294983432Microbix Emailcustomer.service@microbix.com
Microbix Logo
Request Catalogue Contact Us
  • Services
    • Assay Development Solutions
    • Custom Vial Filling Services
  • Products
    • Reference Materials (QUANTDx™)
    • Antigens
      • All Antigens
      • Childhood Disease Antigens
      • Dengue Antigens
      • STI Antigens
      • ToRCH Antigens
      • Respiratory Antigens
      • Other Antigens
    • External Quality Controls (QAPs™)
      • All External QC Products
      • Respiratory Viral Panel
      • STI Panel
      • HPV Panel
      • Gastrointestinal Panel
      • Genital Ulcer Panel
      • Vaginal Infections Panel
      • ONBOARDx Kits
      • Proficiency Testing Panel
      • Technical Resources
    • DxTM™ Viral Transport Medium
    • Control Elution Buffer
    • Kinlytic (Urokinase)
  • About
    • Who We Are
    • Who We Work With
    • Quality
    • Board of Directors
    • Our Senior Team
    • Careers
  • Resources
    • White Papers
    • Poster Publication
    • Podcasts
  • Investors
    • News Releases
    • Financial Reports
    • Corporate Presentations
    • Analyst Coverage
    • Corporate Governance
    • Stock Information
Contact Us

Microbix Supporting Australian Point-of-Care Testing Program

by Pavel Zhelev | Mar 1, 2023 | News Releases

QAPs used in Diagnostic Testing for STIs in Remote Communities MISSISSAUGA, CANADA, March 1, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

by Pavel Zhelev | Feb 9, 2023 | News Releases

Sales of $2.5 million, Net Loss of $1.3 million MISSISSAUGA, February 9, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter ended December 31, 2022...

Microbix Presenting Results of Collaboration with Health PEI

by Pavel Zhelev | Feb 6, 2023 | News Releases

QAPs for HPV Test Verification within Cervical Cancer Screening Program MISSISSAUGA, CANADA, February 6, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting...

Microbix Launches QAP to Support “Monkeypox” Testing

by Pavel Zhelev | Jan 30, 2023 | News Releases

Driven by Customer Requests, Mpox Test Control Now Available MISSISSAUGA, CANADA, January 30, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is launching a new quality...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Record Sales for Fiscal 2022

by Pavel Zhelev | Dec 22, 2022 | Blog, News Releases

Record Sales of $19.1 million, Net Earnings of $1.8 million MISSISSAUGA, December 22, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its year and fourth quarter...
« Older Entries
Next Entries »
  • Investors
  • Legal
  • Contact
  • News Releases
  • Accessibility
  • Careers
Microbix Funded By